Chemotactic peptide-induced acute colitis in rabbits

Area of Science:

• Gastroenterology
• Immunology
• Microbiology

Background:

• Bacterial chemotactic peptides in the gut lumen may trigger inflammation if they penetrate the intestinal mucosa.
• Understanding the role of these peptides in mucosal inflammation is crucial for inflammatory bowel disease (IBD) research.

Purpose of the Study:

• To investigate the in vivo colitis-inducing potential of various bacterial chemotactic peptides in rabbits.
• To assess the ex vivo eicosanoid release stimulated by these peptides from rabbit colons.
• To explore the mechanisms by which these peptides induce colitis, focusing on eicosanoid involvement.

Main Methods:

• Intracolonic administration of chemotactic peptides (n-formyl-methionyl-leucyl-phenylalanine, its methyl ester, alanyl-glycyl-seryl-glutamic acid) and non-chemotactic bradykinin in rabbits.
• Gross and histological assessment of colitis development within 4 days.
• Ex vivo perfusion of normal rabbit colons to measure leukotriene B4, leukotriene C4, and prostaglandin E2 release.

Main Results:

• All tested chemotactic peptides induced colitis in vivo.
• n-Formyl-methionyl-leucyl-phenylalanine methyl ester caused the most severe colitis and significant eicosanoid release (prostaglandin E2, leukotrienes).
• Alanyl-glycyl-seryl-glutamic acid induced colitis without detectable eicosanoid release, suggesting an independent mechanism.

Conclusions:

• Bacterial chemotactic peptides can induce colitis in a rabbit model, mimicking potential mechanisms in human IBD.
• Colitis induction can occur independently of proinflammatory eicosanoids or be exacerbated by their release.
• This model provides insights into the pathogenesis of IBD related to breaches in mucosal defense by luminal peptides.